Paying for the Oncotype DX Test
In the United States
All major insurance carriers cover the Oncotype DX test for eligible patients with early-stage invasive breast cancer. Medicare has established coverage for the Oncotype DX test for patients with DCIS (non-invasive) breast cancer, although coverage outside of Medicare will vary by insurance plan.
In the provinces of British Columbia, Alberta, Saskatchewan Ontario Quebec and Newfoundland, the test is publicly reimbursed on a case-by-case basis, meaning that doctors must seek prior approval for reimbursement before sending tissue to Genomic Health.
For insurance and financial-aid questions, please contact Genomic Health Customer Service: